Michael Delahaye

Director, Team Leader, Cell Therapy Bioprocessing • AstraZeneca

Michael has recently joined the BioPharmaceuticals R&D Cell Therapy Department at AstraZeneca, and brings with him almost 15 years of industrial experience within the cell and gene therapy sector. His key focus is the development and delivery of robust manufacturing processes, supported by rapid, high resolution characterisation tools to facilitate the production of cell therapies.

Previously, Michael held the position of Head of the Viral Vector Industrialisation team at the Cell and Gene Therapy Catapult. He’s led teams of experienced scientists within the Viral Gene Delivery program, responsible for managing the developmental output of the group within collaborative, commercial and supporting R&D operations. Prior to that, he held roles at TAP Biosystems (now part of Sartorius Stedim) and completed his EngD in 2011 following industrial collaboration with both OnyVax Ltd and ReNeuron Plc.

Also speaking

Tim Funnell

Partner • Monograph Capital

David Horna

Co-Founder & Chief Operating Officer • Aglaris

John Liddell

Chief Technologist • CPI

Event Info


Agenda at a Glance

Check out the Agenda at a Glance for Advanced Therapies Europe 2023.

2022 Post-Event Report

Download the post-event report for Advanced Therapies Europe 2022.